Overview

A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer

Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
This study was designed to find out how effective and safe GW786034, is in the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer that has not responded to standard treatment.
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline